Though Cigna’s reimbursement medical home model is still in its very early stages, Bhuvana Sagar, MD, national medical director of Cigna Healthcare, explained that discussing value in healthcare and getting back to smarter spending as well as better outcomes for patients should be the focus of all industry stakeholders.
Though Cigna’s reimbursement medical home model is still in its very early stages, Bhuvana Sagar, MD, national medical director of Cigna Healthcare, explained that discussing value in healthcare and getting back to smarter spending as well as better outcomes for patients should be the focus of all industry stakeholders.
Transcript slightly modified)
Will the information generated from the various value frameworks out there influence reimbursement decisions by Cigna?
Definitely, definitely. So what we’re trying to do is we’re trying to get as much data as possible and at this point with our reimbursement medical home models that we have in place—these have been there only for a short time, relatively a short time, probably about a year—we’re still trying to get data, we’re still trying to get experience with the program, providers are still getting used to it, customers are still trying to get used to it.
So once we have more information, we’re definitely going to look and see what works, what doesn’t work and where the greatest impact is going to be and go from there.
Why do you think we need to have the value discussion in healthcare today?
Well with rising healthcare costs and we can’t continue to ignore them at this point and we as a society need to do something to address the cost. You know, the different stakeholders need to be involved in the discussion and we’ve come to a point where we all understand that the fee-for-service system just seems to be adding a lot of that volume without necessarily affecting the quality of care.
So we want to go back to what’s important. We want to have smarter spending, better outcomes for our patients and overall better healthcare for our patients.
STEER Data Open Door to SMA Gene Therapy for Wider Age Range of Children
March 19th 2025Delivery of onasemnogene abeparvovec into the intrathecal space was safe and effective for children with spinal muscular atrophy (SMA) aged 2 to 17 years, who had previously been shut out of receiving gene therapy.
Read More
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Neurologists Share Tips for Securing Patient Access to Gene Therapies
March 19th 2025Tenacious efforts at every level, from the individual clinician to the hospital to the state to Congress, will be needed to make sure patients can access life-saving gene therapies for neuromuscular diseases.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
EMBARK Data Show Continued Improvements With DMD Gene Therapy
March 19th 2025Data from the EMBARK trial of delandistrogene moxeparvovec in patients with Duchenne muscular dystrophy (DMD) show that benefits in functional outcomes, gene expression, and muscle imaging persist 2 years after receiving the gene therapy.
Read More
How Access to SMA Treatment Varies Globally and by Insurance Type
March 18th 2025Posters presented at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference show that therapeutic advances in treating spinal muscular atrophy (SMA) are not uniformly making it into the hands of patients who could benefit.
Read More